Potent, ATP-competitive Phosphatidylinositol 3-kinase (PI3K) inhibitor (IC50 = 4, 5, 7 and 75 nM for PI3Kα, -γ, -δ, and -β respectively) and mTOR inhibitor. Able to directly induce G1 arrest and inhibit angiogenesis in vitro and potentiate the efficacy of other anticancer agents in vivo.
Shipped at Room Temperature. Store at -20°C. Store under desiccating conditions.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Moon du G et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol45:1027-35 (2014).
Read more (PubMed: 24969552) »
Roper J et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One6:e25132 (2011).
Read more (PubMed: 21966435) »
Maira SM et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther7:1851-63 (2008).
Read more (PubMed: 18606717) »
Serra V et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res68:8022-30 (2008).
Read more (PubMed: 18829560) »